

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	The Hydration Pharmaceuticals Company Limited
ACN	620 385 677

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	George Livery
Date of last notice	2 June 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	20 September 2023
No. of securities held prior to change Mr George Livery and Mrs Lynne Maree Livery Mrs Lynne Maree Livery* Mr George Livery <small>(*George Livery has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, Mrs Livery's securities.)</small>	226,104 Fully Paid Ordinary Shares 100,000 Fully Paid Ordinary Shares 71,429 unlisted options issued under the EIP exercisable at \$0.476 per option and expiring on 22 July 2027
Class	1. Fully Paid Ordinary Shares 2. Unlisted Options
Number acquired	1. 555,555 Fully Paid Ordinary Shares 2. 277,778 Unlisted Options

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	<ol style="list-style-type: none"> \$0.045 per fully paid ordinary share Nil consideration – one attaching option for every two shares subscribed for under the Company's Entitlement Offer.
No. of securities held after change Mr George Livery and Mrs Lynne Maree Livery Mrs Lynne Maree Livery* Mr George Livery <small>(*George Livery has the power to exercise, or control the exercise of, a right to vote attached to the securities and to dispose of, or control the exercise of a power to dispose of, Mrs Livery's securities.)</small>	781,659 Fully Paid Ordinary Shares 277,778 unlisted options exercisable at \$0.07 per option and expiring on 31 December 2025. 100,000 Fully Paid Ordinary Shares 71,429 unlisted options issued under the EIP exercisable at \$0.476 per option and expiring on 22 July 2027
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Participation in the pro rata, non-renounceable entitlement offer announced to the market on 3 August 2023 in the capacity as sub-underwriter. See amended Appendix 3B dated 30 August 2023 for further details.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	

+ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.